HA
NVO

Harfst & Associates’s Novo Nordisk NVO Stock Holding History

Harfst & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-800
Closed -$13K – 276
2017
Q1 		$13K Buy
+800
New +$13.9K 0.01% 221
2016
Q1 		– Sell
-4,156
Closed -$120K – 185
2015
Q4 		$120K Buy
4,156
+572
+16% +$15.8K 0.05% 124
2015
Q3 		$97K Buy
3,584
+880
+33% +$24.9K 0.04% 127
2015
Q2 		$74K Buy
+2,704
New +$76K 0.04% 149

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Harfst & Associates's NVO Position: Q2 2017 in Review

Harfst & Associates sold out of Novo Nordisk (NVO) in Q2 2017, closing a stake of 800 shares — an estimated $13K sold.

Harfst & Associates first reported a position in NVO in Q2 2015 and held it in 4 quarters. The position peaked at $120K in Q4 2015. 484 funds tracked by Wall St. Rank hold NVO as of Q2 2017.

  • Harfst & Associates reported no remaining Novo Nordisk position as of Q2 2017 after selling out during the quarter.
  • Harfst & Associates sold 800 Novo Nordisk shares in Q2 2017, an estimated $13K.
  • Harfst & Associates first reported a position in Novo Nordisk in Q2 2015 and held it in 4 quarters.
  • Harfst & Associates's Novo Nordisk position peaked at $120K in Q4 2015.
  • 484 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2017.

Based on Harfst & Associates's 13F filing for Q2 2017, filed 11 Aug 2017.